Sale

India Diabetes Market

India Diabetes Market Size, Share, Analysis, Trends, Forecast: By Type: Type 1 Diabetes, Type 2 Diabetes, By Treatment Type: Insulin-Based, Non-Insulin-Based, Others; By Doses Form: Tablets and Capsules, Injections, Creams and Gels, Others; Route of Administration: By End User: By Distribution Channel; Supplier Landscape; 2024-2032

India Diabetes Market Outlook

The India diabetes market size was valued at INR 316 billion in 2023, driven by high prevalence of diabetes cases across the region. The market is expected to grow at a CAGR of 16% during the forecast period of 2024-2032, with the values likely to rise from INR 366.56 billion in 2024 to INR 1201.74 billion by 2032.

 

Indian Diabetes Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Diabetes: Introduction

Diabetes is a condition where the body cannot use the insulin produced effectively or the pancreas does not produce enough insulin at all. Insulin is a hormone produced to regulate glucose in the body. There are two categories of diabetes, type 1 and type 2. Type 1 diabetes is based on the amount of insulin produced by the body and type 2 diabetes is based on the management of insulin by the body. Common symptoms include frequent thirst, blurred vision, fatigue, unintentional weight loss and constant urge to urinate.

 

India Diabetes Market Analysis

The diabetes incidence rate in India stands at around 10.1 crores in 2023. The India diabetes market value is driven by the rising awareness among the patients about the symptoms of diabetes, and its ill effects on health, which has majorly intensified the diagnosis and increased the drug treatment rates in the country.

 

Rapid urbanization and developing healthcare infrastructure are also aiding the industry growth of diabetes in India. In addition to this, extending pharmaceutical contract manufacturing, low-cost drug production, and the introduction of advanced technologies have further accelerated the growth of diabetes market in India. In July 2023, the Indian Institute of Technology (IIT) Bhilai and Shiv Nadar University revealed “smart insulin”, which contains an extended period of insulin release that lasts up to 2 days, far greater than the average 12-hour duration of regular insulin.

 

To meet the high India diabetes market demand, leading health platforms for diabetes like the BeatO App have announced their physical clinic collaborations. After launching 5 clinics across Delhi-NCR, the company visions to spread across Uttar Pradesh, Madhya Pradesh, Rajasthan, Gujarat, and Odisha in the next 6 months. Akums Drugs and Pharmaceuticals Limited also received approval for its triple combination diabetes treatment which includes Sitagliptin 100, Pioglitazone 15 and Metformin 1000/500. Therefore, the market is expected to witness significant growth in the forecast period.

 

India Diabetes Market Segmentation

 

Indian Diabetes Market By Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Type

  • Type 1 Diabetes
  • Type 2 Diabetes

 

Market Breakup by Treatment Type

  • Insulin-Based
  • Non-Insulin-Based
  • Others

 

Market Breakup by Doses Form

  • Tablets and Capsules
  • Injections
  • Creams and Gels
  • Others

 

Market Breakup by Route of Administration

  • Oral
  • Parenteral

 

Market Breakup by End User

  • Hospitals
  • Speciality Clinics
  • Homecare Settings
  • Others

 

Market Breakup by Distribution Channel

  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

 

Indian Diabetes Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

India Diabetes Market Overview

The India diabetes market growth is driven by the launch of programs like National Program for Prevention and Control of Non-Communicable Diseases (NP-NCD), which has been launched by the government of India and works on delivering glucometer and drugs for diabetes to the patients. As a part of this program, the region is also experiencing the set-up of new district clinics and community health centers to promote early diagnosis and prevention of the condition. Movements like Fit India, Khelo India and several yoga related activities are also promoted by the Ministry of AYUSH to promote physical activity in all generations.

 

Moreover, the increasing partnerships amongst private and state-owned entities will also contribute significantly to the India diabetes market share and deliver better solutions to diabetic and pre-diabetic patients. Promotional activities to eat healthy are also advocated by prominent institutions like FSSAI. Eat Right Initiative, Safe and Nutritious Food at Home and ‘Aaj se thoda kum’ awareness initiatives are some of the prime examples. Under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), the masses are also set to receive generic medicines like insulin at affordable prices.

 

India Diabetes Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Sun Pharmaceutical Industries Ltd.
  • Biocon Limited
  • Dr. Reddy's Laboratories Ltd.
  • Novo Nordisk India Pvt. Ltd.
  • Sanofi India Limited
  • Eli Lilly and Company (India) Pvt. Ltd.
  • Johnson & Johnson Private Limited
  • Abbott India Limited
  • Glenmark Pharmaceuticals Ltd.
  • AstraZeneca Pharma India Limited
  • Lupin Limited
  • Torrent Pharmaceuticals Ltd.
  • Merck Limited
  • Cadila Healthcare Limited
  • Wockhardt Limited

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Treatment Type
  • Doses Form
  • Route of Administration
  • End User
  • Distribution Channel 
Breakup by Type
  • Type 1 Diabetes
  • Type 2 Diabetes
Breakup by Treatment Type
  • Insulin-Based
  • Non-Insulin-Based
  • Others
Breakup by Doses Form
  • Tablets and Capsules 
  • Injections 
  • Creams and Gels 
  • Others 
Breakup by Route of Administration
  • Oral
  • Parenteral
Breakup by End User
  • Hospitals 
  • Speciality Clinics 
  • Homecare Settings 
  • Others 
Breakup by Distribution Channel 
  • Hospitals Pharmacy 
  • Retail Pharmacy 
  • Online Pharmacy 
  • Others 
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Sun Pharmaceutical Industries Ltd.
  • Biocon Limited
  • Dr. Reddy's Laboratories Ltd.
  • Novo Nordisk India Pvt. Ltd.
  • Sanofi India Limited
  • Eli Lilly and Company (India) Pvt. Ltd.
  • Johnson & Johnson Private Limited
  • Abbott India Limited
  • Glenmark Pharmaceuticals Ltd.
  • AstraZeneca Pharma India Limited
  • Lupin Limited
  • Torrent Pharmaceuticals Ltd.
  • Merck Limited
  • Cadila Healthcare Limited
  • Wockhardt Limited

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Diabetes Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    India Diabetes Epidemiology Analysis
    5.1    Epidemiology Overview (2017-2032) 
    5.2    India Diabetes Epidemiology by Diabetes Type (2017-2032)
    5.3    India Diabetes Epidemiology by Gender (2017-2032)
    5.4    India Diabetes Epidemiology by Treatment Rate (2017-2032)
6     India Diabetes Market Overview 
    6.1     India Diabetes Market Historical Value (2017-2023) 
    6.2     India Diabetes Market Forecast Value (2024-2032)
7     India Diabetes Market Landscape
    7.1    Diabetes Therapeutics: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Diabetes Therapeutics: Product Landscape
        7.2.1    Analysis by Therapy Type
        7.2.2    Analysis by Drug Class
        7.2.3    Analysis by Route of Administration
8    Diabetes Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
    10     India Diabetes Market Dynamics
        10.1    Market Drivers and Constraints
        10.2    SWOT Analysis
        10.3    Porter’s Five Forces Model
        10.4    Key Demand Indicators 
        10.5    Key Price Indicators
        10.6    Industry Events, Initiatives, and Trends  
        10.7    Value Chain Analysis
11     India Diabetes Market Segmentation
    11.1     India Diabetes Market by Type 
        11.1.1    Market Overview 
        11.1.2    Type 1 Diabetes
        11.1.3    Type 2 Diabetes
    11.2     India Diabetes Market by Treatment Type
        11.2.1    Market Overview 
        11.2.2    Insulin-Based
        11.2.3    Non-Insulin-Based
        11.2.4    Others
    11.3    India Diabetes Market by Doses Form 
        11.3.1    Market Overview 
        11.3.2    Tablets and Capsules 
        11.3.3    Injections 
        11.3.4    Creams and Gels 
        11.3.5    Others 
    11.4    India Diabetes Market by Route of Administration 
        11.4.1    Market Overview 
        11.4.2    Oral 
        11.4.3    Parenteral 
    11.5    India Diabetes Market by End User 
        11.5.1    Market Overview 
        11.5.2    Hospitals 
        11.5.3    Speciality Clinics 
        11.5.4    Homecare Settings 
        11.5.5    Others 
    11.6    India Diabetes Market by Distribution Channel 
        11.6.1    Market Overview 
        11.6.2    Hospitals Pharmacy 
        11.6.3    Retail Pharmacy 
        11.6.4    Online Pharmacy 
        11.6.5    Others 
12    Regulatory Framework
13    Patent Analysis

    13.1    Analysis by Type of Patent
    13.2    Analysis by Publication year
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Patent Age
    13.5    Analysis by CPC Analysis
    13.6    Analysis by Patent Valuation 
    13.7    Analysis by Key Players
14    Grants Analysis
    14.1    Analysis by year
    14.2    Analysis by Amount Awarded
    14.3    Analysis by Issuing Authority
    14.4    Analysis by Grant Application
    14.5    Analysis by Funding Institute
    14.6    Analysis by NIH Departments
    14.7    Analysis by Recipient Organization 
15    Clinical Trials Analysis
    15.1     Analysis by Trial Registration Year
    15.2    Analysis by Trial Status
    15.3    Analysis by Trial Phase
    15.4    Analysis by Therapeutic Area
    15.5    Analysis by Geography
16    Funding and Investment Analysis
    16.1    Analysis by Funding Instances
    16.2    Analysis by Type of Funding
    16.3    Analysis by Funding Amount
    16.4    Analysis by Leading Players
    16.5    Analysis by Leading Investors
    16.6    Analysis by Geography
17    Partnership and Collaborations Analysis
    17.1    Analysis by Partnership Instances
    17.2    Analysis by Type of Partnership
    17.3    Analysis by Leading Players
    17.4    Analysis by Geography
18    Supplier Landscape
    18.1    Sun Pharmaceutical Industries Ltd.
        18.1.1    Financial Analysis
        18.1.2    Product Portfolio
        18.1.3    Demographic Reach and Achievements
        18.1.4    Mergers and Acquisitions
        18.1.5    Certifications
    18.2    Biocon Limited
        18.2.1    Financial Analysis
        18.2.2    Product Portfolio
        18.2.3    Demographic Reach and Achievements
        18.2.4    Mergers and Acquisitions
        18.2.5    Certifications
    18.3    Dr. Reddy's Laboratories Ltd.
        18.3.1    Financial Analysis
        18.3.2    Product Portfolio
        18.3.3    Demographic Reach and Achievements
        18.3.4    Mergers and Acquisitions
        18.3.5    Certifications
    18.4    Novo Nordisk India Pvt. Ltd.
        18.4.1    Financial Analysis
        18.4.2    Product Portfolio
        18.4.3    Demographic Reach and Achievements
        18.4.4    Mergers and Acquisitions
        18.4.5    Certifications
    18.5    Sanofi India Limited
        18.5.1    Financial Analysis
        18.5.2    Product Portfolio
        18.5.3    Demographic Reach and Achievements
        18.5.4    Mergers and Acquisitions
        18.5.5    Certifications
    18.6    Eli Lilly and Company (India) Pvt. Ltd.
        18.6.1    Financial Analysis
        18.6.2    Product Portfolio
        18.6.3    Demographic Reach and Achievements
        18.6.4    Mergers and Acquisitions
        18.6.5    Certifications
    18.7    Johnson & Johnson Private Limited
        18.7.1    Financial Analysis
        18.7.2    Product Portfolio
        18.7.3    Demographic Reach and Achievements
        18.7.4    Mergers and Acquisitions
        18.7.5    Certifications
    18.8    Abbott India Limited
        18.8.1    Financial Analysis
        18.8.2    Product Portfolio
        18.8.3    Demographic Reach and Achievements
        18.8.4    Mergers and Acquisitions
        18.8.5    Certifications
    18.9    Glenmark Pharmaceuticals Ltd.
        18.9.1    Financial Analysis
        18.9.2    Product Portfolio
        18.9.3    Demographic Reach and Achievements
        18.9.4    Mergers and Acquisitions
        18.9.5    Certifications
    18.10    AstraZeneca Pharma India Limited
        18.10.1    Financial Analysis
        18.10.2    Product Portfolio
        18.10.3    Demographic Reach and Achievements
        18.10.4    Mergers and Acquisitions
        18.10.5    Certifications
    18.11    Lupin Limited
        18.11.1    Financial Analysis
        18.11.2    Product Portfolio
        18.11.3    Demographic Reach and Achievements
        18.11.4    Mergers and Acquisitions
        18.11.5    Certifications
    18.12    Torrent Pharmaceuticals Ltd.
        18.12.1    Financial Analysis
        18.12.2    Product Portfolio
        18.12.3    Demographic Reach and Achievements
        18.12.4    Mergers and Acquisitions
        18.12.5    Certifications
    18.13    Merck Limited
        18.13.1    Financial Analysis
        18.13.2    Product Portfolio
        18.13.3    Demographic Reach and Achievements
        18.13.4    Mergers and Acquisitions
        18.13.5    Certifications
    18.14    Cadila Healthcare Limited
        18.14.1    Financial Analysis
        18.14.2    Product Portfolio
        18.14.3    Demographic Reach and Achievements
        18.14.4    Mergers and Acquisitions
        18.14.5    Certifications
    18.15    Wockhardt Limited
        18.15.1    Financial Analysis
        18.15.2    Product Portfolio
        18.15.3    Demographic Reach and Achievements
        18.15.4    Mergers and Acquisitions
        18.15.5    Certifications
19    Diabetes - Distribution Model (Additional Insight)
    19.1    Overview 
    19.2    Potential Distributors 
    19.3    Key Parameters for Distribution Partner Assessment 
20    Key Opinion Leaders (KOL) Insights (Additional Insight)
21    Company Competitiveness Analysis (Additional Insight)

    21.1    Very Small Companies
    21.2    Small Companies
    21.3    Mid-Sized Companies
    21.4    Large Companies
    21.5    Very Large Companies
22    Payment Methods (Additional Insight)
    22.1    Government Funded
    22.2    Private Insurance
    22.3    Out-of-Pocket
    

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about INR 316 billion in 2023, driven by rising incidence of diabetes cases in the region.

The market is anticipated to grow at a CAGR of 16% during the forecast period of 2024-2032, likely to reach a market value of INR 1201.74 billion by 2032.

The market demand is driven by increasing government and private institution driven awareness initiatives among the patients about the symptoms and treatment of diabetes.

The current market trend is driven by the advent of new technical inventions. In July 2023, IIT Bhilai and Shiv Nadar University collaborated to develop a “smart insulin”.

Diabetes can be divided into type 1 diabetes and type 2 diabetes.

Treatment types include insulin-based and non-insulin-based, among others.

Dose forms include tablets and capsules, injections, creams and gels, among others.

Major distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others.

Major end users include hospitals, speciality clinics, and homecare settings, among others.

The route of administration can be oral or parenteral.

Key players involved in the market are Sun Pharmaceutical Industries Ltd., Biocon Limited, Dr. Reddy's Laboratories Ltd., Novo Nordisk India Pvt. Ltd., Sanofi India Limited, Eli Lilly and Company (India) Pvt. Ltd., Johnson & Johnson Private Limited, Abbott India Limited, Glenmark Pharmaceuticals Ltd., AstraZeneca Pharma India Limited, Lupin Limited, Torrent Pharmaceuticals Ltd., Merck Limited, Cadila Healthcare Limited and Wockhardt Limited.

Purchase Full Report

Mini Report

$ 3499     $1999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $2999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 7999     $3999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 9999     $5999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER